Discover how retina models are revolutionizing rare disease treatment and accelerating drug development.
Lilly touts topline late-phase data for once-weekly insulin in race to enter US market
As Novo Nordisk stares down an FDA adcomm later this month to discuss its once-weekly insulin, Eli Lilly is working on its own, sharing positive